-
1.
Merck’s Phase 3 KEYNOTE-B96 trial met its PFS endpoint in platinum-resistant ovarian cancer, both in PD-L1–positive and all patients
-
(Press Releases)
-
Merck known as MSD outside of the United States and Canada, announced that the Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, met its primary endpoint of progression-free survival (PFS) for the treatment ...
-
2.
Servier Announces Positive Long-Term Results from Phase 3 INDIGO Trial on VORANIGO® (vorasidenib), Published in The Lancet Oncology
-
(Press Releases)
-
... 7, 2023, median follow-up was 20.1 months. Key findings from the newly published analysis include: Median progression-free survival (PFS) improved with VORANIGO (not estimable [NE] [95% CI, 22.1-NE]) ...
-
3.
At five years, Libtayo® (cemiplimab) plus chemotherapy results reinforce significant and durable improvements in survival outcomes for advanced non-small cell lung cancer
-
(Press Releases)
-
... 0.53–0.83). The five-year probability of survival was 19.4% for the Libtayo combination versus 8.8% for chemotherapy. 8.2-month median progression-free survival (PFS) versus 5.5 months, representing a ...
-
4.
Incyte announces FDA approval of Monjuvi® (tafasitamab-cxix) with Rituximab and Lenalidomide for relapsed or refractory follicular lymphoma
-
(Press Releases)
-
... in progression-free survival (PFS) by investigator assessment, which demonstrated 27.5% (N=273) of patients with an event in the Monjuvi group vs. 47.6% (N=275) of patients with an event in the control ...
-
5.
FDA Approves Genentech’s Vabysmo Prefilled Syringe for Three Leading Causes of Vision Loss
-
(Press Releases)
-
Genentech, a member of the Roche Group announced the U.S. Food and Drug Administration (FDA) has approved the Vabysmo® (faricimab-svoa) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment ...
-
6.
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
-
(Press Releases)
-
... survival (PFS) analysis of the ALPINE trial, we believe BRUKINSA is well-positioned to become the BTKi of choice across multiple indications,” said Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, ...
-
7.
Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (LONSURF®)
-
(Press Releases)
-
Servier and Taiho Oncology, Inc., the release of data from SUNLIGHT, a pivotal Phase 3 global trial evaluating the combination of trifluridine/tipiracil (LONSURF®).
And bevacizumab in adults with refractory ...
